BridgeMD
New treatment option for Intracerebral Hemorrhage
Official title Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control
ClinicalTrials.gov ID: NCT07458880
What this study is testing
What is Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide?
Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for intracerebral hemorrhage.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Intracerebral hemorrhage (ICH) is the second most common form of stroke, with an incidence of around 3000 cases per year in Hong Kong. Although it only accounts for around 20-30% of all strokes, ICH is the most severe form of stroke, contributing to 50% of all stroke mortality and the greatest disability burden in stroke.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Spontaneous ICH
- Age ≥18 years
- Premorbid modified Rankin Scale of ≤3
- TRICH score ≥3
- Within 1 week of ICH
You likely can't join if
- Glasgow coma score \<9
- Expected life expectancy of six months
- Admission SBP \<160mmHg
- Severe renal impairment, estimated glomerular filtration rate using CKD-EPI formula \<30 ml/min/1.73m2
- Inability to perform home BP monitoring
- Inability to participate in follow-up activity
See the full eligibility criteria
- Spontaneous ICH
- Age ≥18 years
- Premorbid modified Rankin Scale of ≤3
- TRICH score ≥3
- Within 1 week of ICH
- Glasgow coma score \<9
- Expected life expectancy of six months
- Admission SBP \<160mmHg
- Severe renal impairment, estimated glomerular filtration rate using CKD-EPI formula \<30 ml/min/1.73m2
- Inability to perform home BP monitoring
- Inability to participate in follow-up activity
- Hypersensitivity to study drug
- Known contraindication to amlodipine
- Known contraindication to valsartan
- Known contraindication to hydrochlorothiazide
- Any conditions that investigator deems that patient is not suitable of any component of the triple pill or antihypertensive medications in general
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong, Hong Kong
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.